



Clinical trial results:

A randomized phase II study evaluating FOLFIRI + durvalumab vs FOLFIRI + durvalumab and tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

Summary

EudraCT number	2018-002014-13
Trial protocol	FR
Global end of trial date	13 September 2024

Results information

Result version number	v1 (current)
This version publication date	26 October 2025
First version publication date	26 October 2025

Trial information

Trial identification

Sponsor protocol code	PRODIGE59-(FFCD1707)-DURIGAST
-----------------------	-------------------------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03959293
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Fédération Francophone de Cancérologie Digestive
Sponsor organisation address	7 bd Jeanne d'Arc, Dijon, France, 21000
Public contact	Project Manager, Fédération Francophone de Cancérologie Digestive, +33 380393483, marie.moreau@u-bourgogne.fr
Scientific contact	Head of biostatistics, Fédération Francophone de Cancérologie Digestive, +33 380668013, karine.le-malicot@u-bourgogne.fr

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 January 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 January 2023
Global end of trial reached?	Yes
Global end of trial date	13 September 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Percentage of patients alive and without progression at 4 months of FOLFIRI plus durvalumab versus FOLFIRI plus durvalumab plus tremelimumab in patients with advanced-stage gastric or gastro-oesophageal junction adenocarcinoma and who progressed after a first line chemotherapy (based on RECIST 1.1 rating scale evaluated by the investigator).

Protection of trial subjects:

The study complies with the Declaration of Helsinki and the principles of Good Clinical Practice guidelines. Informed consent was obtained prior to inclusion of each patient.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 January 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects**Subjects enrolled per country**

Country: Number of subjects enrolled	France: 96
Worldwide total number of subjects	96
EEA total number of subjects	96

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	61
From 65 to 84 years	35
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Between August 27, 2020 and June 4, 2021, 96 patients in 37 centres were randomised and 92 patients received one or more doses of the treatment (mITT population, n=92, 47 in FD arm and 45 in FDT arm). One patient randomized in the FD arm received the FDT treatment and was analysed in the FDT arm for safety analyses.

Pre-assignment

Screening details:

Main inclusion criteria were patients aged 18 years or older, histologically proven advanced unresectable (locally advanced or metastatic) gastric/GEJ (Siewert 2 or 3) adenocarcinoma, with progression or intolerance after first-line chemotherapy with fluoropyrimidine plus platinum salt +/- taxane +/- anti-HER2 therapies, PS 0 or 1.

Period 1

Period 1 title	ITT
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	FOLFIRI plus durvalumab (FD arm)

Arm description:

FOLFIRI regimen with folinic acid 400 mg/m², a 5FU bolus 400 mg/m², continuous 5FU 2400 mg/m² and irinotecan at 180 mg/m², every 2 weeks. Durvalumab was administered at a dose of 1500 mg, every 4 weeks

Arm type	Active comparator
Investigational medicinal product name	LV5FU2
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous bolus use , Intravenous use

Dosage and administration details:

folinic acid 400 mg/m², a 5FU bolus 400 mg/m², continuous 5FU 2400 mg/m²

Investigational medicinal product name	Irinotecan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Irinotecan at 180 mg/m², every 2 weeks

Investigational medicinal product name	Durvalumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Durvalumab was administered at a dose of 1500 mg, every 4 weeks

Arm title	FOLFIRI plus durvalumab and tremelimumab (FDT arm)
------------------	--

Arm description:

FOLFIRI regimen with folinic acid 400 mg/m², a 5FU bolus 400 mg/m², continuous 5FU 2400 mg/m²

and irinotecan at 180 mg/m², every 2 weeks. Durvalumab was administered at a dose of 1500 mg, every 4 weeks. Tremelimumab was administered at a dose of 75 mg, every 4 weeks. Tremelimumab was administered for only four cycles

Arm type	Experimental
Investigational medicinal product name	LV5FU2
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous bolus use , Intravenous use

Dosage and administration details:

folinic acid 400 mg/m², a 5FU bolus 400 mg/m², continuous 5FU 2400 mg/m²

Investigational medicinal product name	Irinotecan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Irinotecan at 180 mg/m², every 2 weeks

Investigational medicinal product name	Durvalumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Durvalumab was administered at a dose of 1500 mg, every 4 weeks

Investigational medicinal product name	Tremelimumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Tremelimumab was administered at a dose of 75 mg, every 4 weeks for only four cycles

Number of subjects in period 1	FOLFIRI plus durvalumab (FD arm)	FOLFIRI plus durvalumab and tremelimumab (FDT arm)
Started	48	48
Patients not treated	1 ^[1]	3 ^[2]
Completed	47	45
Not completed	1	3
Death	1	-
Patients not treated	-	3

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: One patient died before the start of treatment

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: 3 patients were never treated in the protocol

Period 2

Period 2 title	Treatment period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	FOLFIRI plus durvalumab (FD arm)

Arm description: -

Arm type	Active comparator
Investigational medicinal product name	LV5FU2
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous bolus use , Intravenous use

Dosage and administration details:

folinic acid 400 mg/m², a 5FU bolus 400 mg/m², continuous 5FU 2400 mg/m²

Investigational medicinal product name	Irinotecan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Irinotecan at 180 mg/m², every 2 weeks

Investigational medicinal product name	Durvalumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Durvalumab was administered at a dose of 1500 mg, every 4 weeks

Arm title	FOLFIRI plus durvalumab and tremelimumab (FDT arm)
------------------	--

Arm description: -

Arm type	Active comparator
Investigational medicinal product name	LV5FU2
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous bolus use , Intravenous use

Dosage and administration details:

folinic acid 400 mg/m², a 5FU bolus 400 mg/m², continuous 5FU 2400 mg/m²

Investigational medicinal product name	Irinotecan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Irinotecan at 180 mg/m², every 2 weeks

Investigational medicinal product name	Durvalumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Durvalumab was administered at a dose of 1500 mg, every 4 weeks

Investigational medicinal product name	Tremelimumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Tremelimumab was administered at a dose of 75 mg, every 4 weeks for only four cycles

Number of subjects in period 2	FOLFIRI plus durvalumab (FD arm)	FOLFIRI plus durvalumab and tremelimumab (FDT arm)
Started	47	45
Completed	47	45

Baseline characteristics

Reporting groups

Reporting group title	FOLFIRI plus durvalumab (FD arm)
Reporting group description: FOLFIRI regimen with folinic acid 400 mg/m ² , a 5FU bolus 400 mg/m ² , continuous 5FU 2400 mg/m ² and irinotecan at 180 mg/m ² , every 2 weeks. Durvalumab was administered at a dose of 1500 mg, every 4 weeks	
Reporting group title	FOLFIRI plus durvalumab and tremelimumab (FDT arm)
Reporting group description: FOLFIRI regimen with folinic acid 400 mg/m ² , a 5FU bolus 400 mg/m ² , continuous 5FU 2400 mg/m ² and irinotecan at 180 mg/m ² , every 2 weeks. Durvalumab was administered at a dose of 1500 mg, every 4 weeks. Tremelimumab was administered at a dose of 75 mg, every 4 weeks. Tremelimumab was administered for only four cycles	

Reporting group values	FOLFIRI plus durvalumab (FD arm)	FOLFIRI plus durvalumab and tremelimumab (FDT arm)	Total
Number of subjects	48	48	96
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	30	31	61
From 65-84 years	18	17	35
85 years and over	0	0	0
Gender categorical			
Units: Subjects			
Female	14	14	28
Male	34	34	68

End points

End points reporting groups

Reporting group title	FOLFIRI plus durvalumab (FD arm)
Reporting group description: FOLFIRI regimen with folinic acid 400 mg/m ² , a 5FU bolus 400 mg/m ² , continuous 5FU 2400 mg/m ² and irinotecan at 180 mg/m ² , every 2 weeks. Durvalumab was administered at a dose of 1500 mg, every 4 weeks	
Reporting group title	FOLFIRI plus durvalumab and tremelimumab (FDT arm)
Reporting group description: FOLFIRI regimen with folinic acid 400 mg/m ² , a 5FU bolus 400 mg/m ² , continuous 5FU 2400 mg/m ² and irinotecan at 180 mg/m ² , every 2 weeks. Durvalumab was administered at a dose of 1500 mg, every 4 weeks. Tremelimumab was administered at a dose of 75 mg, every 4 weeks. Tremelimumab was administered for only four cycles	
Reporting group title	FOLFIRI plus durvalumab (FD arm)
Reporting group description: -	
Reporting group title	FOLFIRI plus durvalumab and tremelimumab (FDT arm)
Reporting group description: -	

Primary: 4-months PFS

End point title	4-months PFS ^[1]
End point description:	
End point type	Primary
End point timeframe: within 4 months after the randomization	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This study is a non comparative study that is why no inferential statistics are provided	

End point values	FOLFIRI plus durvalumab (FD arm)	FOLFIRI plus durvalumab and tremelimumab (FDT arm)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	47	45		
Units: patients				
Patients with progression/death at 4 months	25	20		
Patient without progression/death at 4 months	21	25		
Patient not evaluable	1	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival

End point title	Overall Survival
-----------------	------------------

End point description:

It was defined by the time between the date of randomization and the date of death (from any cause);
Alive patients were censored at the date of last news .

End point type	Secondary
----------------	-----------

End point timeframe:

18 months

End point values	FOLFIRI plus durvalumab (FD arm)	FOLFIRI plus durvalumab and tremelimumab (FDT arm)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	47	45		
Units: months				
median (confidence interval 95%)	20.3 (17.97 to 21.95)	23.16 (17.91 to 23.49)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events were collected before each cycle of chemotherapy systematically during the whole protocol of treatment

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	NCI-CTC
-----------------	---------

Dictionary version	4.0
--------------------	-----

Reporting groups

Reporting group title	FOLFIRI plus durvalumab (FD arm)
-----------------------	----------------------------------

Reporting group description:

1 patient randomized in the FD arm received Tremelimumb so the patient was considered in the FDT arm for safety

Reporting group title	FOLFIRI plus durvalumab and tremelimumab (FDT arm)
-----------------------	--

Reporting group description:

1 patient randomized in the FD arm received Tremelimumab so the patient was considered in the FDT arm for safety

Serious adverse events	FOLFIRI plus durvalumab (FD arm)	FOLFIRI plus durvalumab and tremelimumab (FDT arm)	
Total subjects affected by serious adverse events			
subjects affected / exposed	23 / 46 (50.00%)	45 / 46 (97.83%)	
number of deaths (all causes)	36	35	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to central nervous system			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour haemorrhage			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Vascular disorders			
Hypotension			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemic shock			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superior vena cava syndrome			
subjects affected / exposed	1 / 46 (2.17%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Prostatic operation			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 46 (0.00%)	2 / 46 (4.35%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			

subjects affected / exposed	3 / 46 (6.52%)	6 / 46 (13.04%)	
occurrences causally related to treatment / all	1 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mucosal inflammation			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstruction			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	1 / 46 (2.17%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Social circumstances			
Disability			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	1 / 46 (2.17%)	2 / 46 (4.35%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung disorder			

subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	0 / 46 (0.00%)	2 / 46 (4.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oxygen consumption decreased			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Gastrostomy failure			

subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrostomy tube site complication			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 46 (2.17%)	2 / 46 (4.35%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemolytic anaemia			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fistula			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	2 / 46 (4.35%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	1 / 46 (2.17%)	6 / 46 (13.04%)	
occurrences causally related to treatment / all	1 / 1	5 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			

subjects affected / exposed	2 / 46 (4.35%)	4 / 46 (8.70%)	
occurrences causally related to treatment / all	0 / 2	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal obstruction			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	3 / 46 (6.52%)	3 / 46 (6.52%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			
subjects affected / exposed	0 / 46 (0.00%)	2 / 46 (4.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	2 / 46 (4.35%)	2 / 46 (4.35%)	
occurrences causally related to treatment / all	2 / 2	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			
subjects affected / exposed	3 / 46 (6.52%)	3 / 46 (6.52%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	2 / 46 (4.35%)	6 / 46 (13.04%)	
occurrences causally related to treatment / all	1 / 2	3 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholangitis			

subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholestasis			
subjects affected / exposed	2 / 46 (4.35%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis acute			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice cholestatic			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Bone pain			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Clostridium colitis			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Endocarditis			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal sepsis			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung abscess			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal abscess			
subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	2 / 46 (4.35%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	4 / 46 (8.70%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	3 / 4	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			

subjects affected / exposed	0 / 46 (0.00%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	1 / 46 (2.17%)	0 / 46 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Starvation			
subjects affected / exposed	1 / 46 (2.17%)	1 / 46 (2.17%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	FOLFIRI plus durvalumab (FD arm)	FOLFIRI plus durvalumab and tremelimumab (FDT arm)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	45 / 46 (97.83%)	45 / 46 (97.83%)	
Investigations			
ALAT increase			
subjects affected / exposed	9 / 46 (19.57%)	9 / 46 (19.57%)	
occurrences (all)	9	9	
ASAT increase			
subjects affected / exposed	9 / 46 (19.57%)	14 / 46 (30.43%)	
occurrences (all)	9	14	
Creatinine increase			
subjects affected / exposed	6 / 46 (13.04%)	4 / 46 (8.70%)	
occurrences (all)	6	4	
GGT increase			
subjects affected / exposed	14 / 46 (30.43%)	15 / 46 (32.61%)	
occurrences (all)	14	15	
White blood cell decrease			
subjects affected / exposed	10 / 46 (21.74%)	13 / 46 (28.26%)	
occurrences (all)	10	13	
PNN decrease			

subjects affected / exposed	21 / 46 (45.65%)	22 / 46 (47.83%)	
occurrences (all)	21	22	
Lymphocytes decrease			
subjects affected / exposed	14 / 46 (30.43%)	17 / 46 (36.96%)	
occurrences (all)	14	17	
Weight loss			
subjects affected / exposed	2 / 46 (4.35%)	7 / 46 (15.22%)	
occurrences (all)	2	7	
PAL Increase			
subjects affected / exposed	15 / 46 (32.61%)	19 / 46 (41.30%)	
occurrences (all)	15	19	
Platelets decrease			
subjects affected / exposed	10 / 46 (21.74%)	10 / 46 (21.74%)	
occurrences (all)	10	10	
Vascular disorders			
Thromboembolic event			
subjects affected / exposed	1 / 46 (2.17%)	4 / 46 (8.70%)	
occurrences (all)	1	4	
Nervous system disorders			
Cephalgia			
subjects affected / exposed	4 / 46 (8.70%)	2 / 46 (4.35%)	
occurrences (all)	4	2	
Dysgueusia			
subjects affected / exposed	2 / 46 (4.35%)	3 / 46 (6.52%)	
occurrences (all)	2	3	
Sensitive peripheral neuropathy			
subjects affected / exposed	10 / 46 (21.74%)	10 / 46 (21.74%)	
occurrences (all)	10	10	
Nevralgia			
subjects affected / exposed	3 / 46 (6.52%)	2 / 46 (4.35%)	
occurrences (all)	3	2	
Paresthesia			
subjects affected / exposed	8 / 46 (17.39%)	7 / 46 (15.22%)	
occurrences (all)	8	7	
Blood and lymphatic system disorders			

Anemia subjects affected / exposed occurrences (all)	34 / 46 (73.91%) 34	38 / 46 (82.61%) 38	
General disorders and administration site conditions			
Fatigue subjects affected / exposed occurrences (all)	36 / 46 (78.26%) 36	38 / 46 (82.61%) 38	
Fever subjects affected / exposed occurrences (all)	4 / 46 (8.70%) 4	3 / 46 (6.52%) 3	
Gastrointestinal disorders			
Dry mouth subjects affected / exposed occurrences (all)	2 / 46 (4.35%) 2	3 / 46 (6.52%) 3	
Constipation subjects affected / exposed occurrences (all)	10 / 46 (21.74%) 10	11 / 46 (23.91%) 11	
Diarrhoea subjects affected / exposed occurrences (all)	25 / 46 (54.35%) 25	35 / 46 (76.09%) 35	
Abdominal pain subjects affected / exposed occurrences (all)	10 / 46 (21.74%) 10	12 / 46 (26.09%) 12	
Stomach pain subjects affected / exposed occurrences (all)	9 / 46 (19.57%) 9	7 / 46 (15.22%) 7	
Dysphagia subjects affected / exposed occurrences (all)	8 / 46 (17.39%) 8	8 / 46 (17.39%) 8	
Gastroesophageal reflux subjects affected / exposed occurrences (all)	8 / 46 (17.39%) 8	2 / 46 (4.35%) 2	
Mucositis subjects affected / exposed occurrences (all)	10 / 46 (21.74%) 10	21 / 46 (45.65%) 21	
Nausea			

subjects affected / exposed occurrences (all)	31 / 46 (67.39%) 31	28 / 46 (60.87%) 28	
Vomiting subjects affected / exposed occurrences (all)	15 / 46 (32.61%) 15	18 / 46 (39.13%) 18	
Respiratory, thoracic and mediastinal disorders			
Dyspnea subjects affected / exposed occurrences (all)	6 / 46 (13.04%) 6	9 / 46 (19.57%) 9	
Cough subjects affected / exposed occurrences (all)	5 / 46 (10.87%) 5	2 / 46 (4.35%) 2	
Skin and subcutaneous tissue disorders			
Alopecia subjects affected / exposed occurrences (all)	7 / 46 (15.22%) 7	12 / 46 (26.09%) 12	
Pruritus subjects affected / exposed occurrences (all)	6 / 46 (13.04%) 6	9 / 46 (19.57%) 9	
Acneiform rash subjects affected / exposed occurrences (all)	4 / 46 (8.70%) 4	5 / 46 (10.87%) 5	
Palmar-plantar erythrodysesthesia syndrome subjects affected / exposed occurrences (all)	6 / 46 (13.04%) 6	7 / 46 (15.22%) 7	
Dry skin subjects affected / exposed occurrences (all)	3 / 46 (6.52%) 3	4 / 46 (8.70%) 4	
Endocrine disorders			
Hyperthyroidism subjects affected / exposed occurrences (all)	2 / 46 (4.35%) 2	8 / 46 (17.39%) 8	
Hypothyroidism subjects affected / exposed occurrences (all)	4 / 46 (8.70%) 4	7 / 46 (15.22%) 7	
Musculoskeletal and connective tissue			

disorders			
Dorsalgia			
subjects affected / exposed	6 / 46 (13.04%)	3 / 46 (6.52%)	
occurrences (all)	6	3	
Myalgia			
subjects affected / exposed	4 / 46 (8.70%)	5 / 46 (10.87%)	
occurrences (all)	4	5	
Metabolism and nutrition disorders			
Anorexia			
subjects affected / exposed	13 / 46 (28.26%)	23 / 46 (50.00%)	
occurrences (all)	13	23	
Hyperglycemia			
subjects affected / exposed	7 / 46 (15.22%)	5 / 46 (10.87%)	
occurrences (all)	7	5	
Hyperkalemia			
subjects affected / exposed	5 / 46 (10.87%)	6 / 46 (13.04%)	
occurrences (all)	5	6	
Hypoalbuminemia			
subjects affected / exposed	4 / 46 (8.70%)	7 / 46 (15.22%)	
occurrences (all)	4	7	
Hypocalcemia			
subjects affected / exposed	7 / 46 (15.22%)	9 / 46 (19.57%)	
occurrences (all)	7	9	
Hypokalemia			
subjects affected / exposed	2 / 46 (4.35%)	4 / 46 (8.70%)	
occurrences (all)	2	4	
Hyponatremia			
subjects affected / exposed	4 / 46 (8.70%)	6 / 46 (13.04%)	
occurrences (all)	4	6	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/38573643>

<http://www.ncbi.nlm.nih.gov/pubmed/33358124>

<http://www.ncbi.nlm.nih.gov/pubmed/35625947>